{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:11:18Z","timestamp":1774278678178,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100303","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T12:55:50Z","timestamp":1636808150000},"page":"100303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation"],"prefix":"10.1016","volume":"6","author":[{"given":"E.E.A.P.","family":"Mulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmoop.2021.100303_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc.2017.43","article-title":"Melanoma: a global perspective","volume":"17","author":"Ossio","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2021.100303_bib2","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/annonc\/mdp252","article-title":"Epidemiology of invasive cutaneous melanoma","volume":"20","author":"MacKie","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100303_bib3","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100303_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma","volume":"119","author":"Kanaki","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100303_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100303_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100303_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100303_bib8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100303_bib9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100303_bib10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100303_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","article-title":"Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma","volume":"59","author":"Moser","year":"2020","journal-title":"Acta Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2021.100303_bib12","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100303_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"6892","key":"10.1016\/j.esmoop.2021.100303_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.esmoop.2021.100303_bib15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100303_bib16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100303_bib17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100303_bib18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100303_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100303_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100303_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100303_bib22","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria","volume":"29","author":"van der Ploeg","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100303_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100303_bib24","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2021.100303_bib25","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100303_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100303_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmoop.2021.100303_bib29","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"key":"10.1016\/j.esmoop.2021.100303_bib31","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100303_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers12041003","article-title":"Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs","volume":"12","author":"Leeneman","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100303_bib34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100303_bib35","series-title":"Cost-effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.esmoop.2021.100303_bib40","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100303_bib41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjd.12346","article-title":"Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991","volume":"169","author":"Holterhues","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100303_bib42","doi-asserted-by":"crossref","first-page":"e0197780","DOI":"10.1371\/journal.pone.0197780","article-title":"Willingness to pay for a cure of low-risk melanoma patients in Germany","volume":"13","author":"Augustin","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100303_bib44","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2021.100303_bib45","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100303_bib46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.07.011","article-title":"Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors","volume":"137","author":"Coart","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100303_bib47","article-title":"Cost-effectiveness analysis of adjuvant therapy for BRAF-mutant resected stage III melanoma in medicare patients","author":"Mojtahed","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100303_bib48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40261-020-00922-6","article-title":"An economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma in the USA","volume":"40","author":"Bensimon","year":"2020","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100303_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1470-2045(15)00486-6","article-title":"Actual costs of cancer drugs in 15 European countries","volume":"17","author":"van Harten","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100303_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.02.016","article-title":"Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact?","volume":"113","author":"Bayle","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100303_bib51","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.2888","article-title":"Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center","volume":"9","author":"Hall","year":"2020","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100303_bib52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","article-title":"Fixed dosing of monoclonal antibodies in oncology","volume":"22","author":"Hendrikx","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100303_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-021-08018-w","article-title":"Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial","volume":"21","author":"Mulder","year":"2021","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100303_bib54","first-page":"256","article-title":"Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study","volume":"43","author":"van Zeijl","year":"2020","journal-title":"J\u00a0Immunother"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100303_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100303_bib56","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/cancers11121950","article-title":"Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review","volume":"11","author":"Greco","year":"2019","journal-title":"Cancers"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2021.100303_bib58","first-page":"S1283","article-title":"LBA3_PR \u2013 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial","volume":"32","author":"Luke","year":"2021","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:29Z","timestamp":1761855929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2059702921002659"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100303","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100303"}}